Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
5hon MSN
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback